Treatment of Light-Chain (AL) Amyloidosis

Diagnostic Confirmation

• The American College of Cardiology recommends accurate monoclonal protein screening, which requires serum free light chain assay (sFLC), serum immunofixation electrophoresis (SIFE), and urine immunofixation electrophoresis (UIFE) for the diagnosis of AL amyloidosis 1, 2
• Standard protein electrophoresis (SPEP/UPEP) should not be used alone due to lower sensitivity, as per the American College of Cardiology guidelines 1
• Bone marrow biopsy is necessary to demonstrate clonal proliferation of lambda or kappa-producing plasma cells, according to the American College of Cardiology 2

Treatment Algorithm

• The American College of Cardiology suggests considering high-dose melphalan followed by autologous stem cell transplantation for ASCT-eligible patients 1, 3
• Daratumumab-CyBorD may be considered as first-line therapy for ASCT-eligible patients, based on recent evidence from the American College of Cardiology 1, 3
• For ASCT-ineligible patients, the American College of Cardiology recommends Daratumumab-CyBorD as the preferred first-line option 1, 3
• Alternative treatment options include CyBorD (cyclophosphamide, bortezomib, and dexamethasone), as suggested by the American College of Cardiology and Blood Cancer Journal 1, 4

Medication Details and Considerations

• The American College of Cardiology notes that daratumumab (anti-CD38 antibody) is recently FDA-approved for AL amyloidosis and has potential cardiac toxicities, including cardiac failure (12%), arrhythmias (8%), and atrial fibrillation (6%) 1, 3
• Proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib, have associated risks, including Grade 3 heart failure, decreased LVEF, and pulmonary hypertension, as reported by the American College of Cardiology 3
• Immunomodulatory agents, such as lenalidomide, pomalidomide, and thalidomide, can cause cardiac and renal concerns, according to the American College of Cardiology 3
• Corticosteroids, such as dexamethasone and prednisone, require monitoring for peripheral edema, pulmonary edema, and fluid overload, as per the American College of Cardiology guidelines 3

Important Clinical Considerations

• The goal of treatment is to eradicate pathological plasma cells and remove affected light chains from circulation, as stated by the American College of Cardiology 1
• Cardiac involvement is the main driver of disease prognosis and mortality, according to Blood Cancer Journal 4
• Collaboration between hematologists, cardiologists, and nephrologists is crucial for effective treatment, as recommended by the American College of Cardiology 1

Common Pitfalls and Caveats

• The American College of Cardiology notes that there are no absolute contraindications to plasma cell-directed therapies based on ejection fraction or cardiac status in AL cardiac amyloidosis 1
• Differentiation between AL amyloidosis and transthyretin (TTR) amyloidosis is essential, as management differs significantly, according to Blood Cancer Journal 4
• Patients with AL amyloidosis are at higher risk for treatment-related toxicity than those with multiple myeloma, as reported by the American College of Cardiology 1
• Close monitoring for cardiac decompensation during therapy is essential, as recommended by the American College of Cardiology 1, 3

Management and Treatment of Amyloidosis

Introduction to Amyloidosis

• The American College of Cardiology recommends early diagnosis and targeted therapy for amyloidosis, with AL amyloidosis treatment being primarily transplant-driven or bortezomib-based, while TTR amyloidosis requires different targeted therapies 5, 6

Types of Amyloidosis and Diagnostic Approach

• AL (light chain) amyloidosis is the most common type, associated with plasma cell disorders, and is characterized by extracellular deposition of misfolded proteins in tissues, leading to organ dysfunction 5, 7
• ATTR (transthyretin) amyloidosis is either wild-type (age-related) or variant (hereditary) and requires different targeted therapies 8
• AA (secondary) amyloidosis is associated with chronic inflammatory conditions 9
• Diagnosis of amyloidosis requires tissue biopsy with Congo Red staining showing characteristic apple-green birefringence under polarized light, and typing of amyloid protein using mass spectrometry (gold standard), immunohistochemistry, or immunofluorescence 10

Treatment of AL Amyloidosis

• The National Comprehensive Cancer Network recommends autologous stem cell transplantation (ASCT) as the standard of care for eligible AL amyloidosis patients, with eligibility criteria including adequate cardiac function, good performance status, and limited organ involvement 5, 6, 11, 12
• Bortezomib-based regimens are the backbone of treatment for ASCT-ineligible patients, with options including bortezomib, cyclophosphamide, and dexamethasone (VCD), and daratumumab (anti-CD38 antibody) 5, 6, 12, 13
• Treatment goals include achieving deep hematologic responses, minimizing treatment-related toxicity, and preventing further organ damage 5, 6

Treatment of ATTR Amyloidosis

• The American College of Cardiology recommends differentiation from AL amyloidosis and targeted therapies such as tafamidis for TTR cardiac amyloidosis 8, 11

Management of Organ-Specific Complications

• The American College of Cardiology recommends careful fluid balance and neurohormonal antagonists (ACE inhibitors, ARBs, beta-blockers) for heart failure management, and heart transplantation may be considered in select patients without significant extracardiac involvement 11
• The National Kidney Foundation recommends supportive care including blood pressure control and eventually dialysis if needed, and renal transplantation may be considered in selected patients 9

Monitoring and Follow-up

• Regular monitoring of hematologic response, organ function, and serum amyloid A (SAA) protein and CRP as markers of inflammation is crucial for early detection of relapse/refractory disease 5, 6, 9

Prognosis

• The American College of Cardiology states that cardiac involvement is the main driver of disease prognosis and mortality, and deep hematologic responses correlate with improved organ function and survival 5, 7

Multidisciplinary Approach to Amyloidosis Management

Core Specialist Team for Amyloidosis Management

• The American College of Cardiology recommends that a hematologist serves as the primary specialist for managing amyloidosis, directing anti-plasma cell therapies and coordinating overall care 14
• A cardiologist is essential for managing cardiac involvement, which is present in most cases and is the main driver of mortality 14, 15
• A nephrologist manages kidney involvement, proteinuria, and renal dysfunction that frequently occur in amyloidosis 16
• A gastroenterologist addresses GI tract involvement, malabsorption, and other digestive complications 14, 15, 17

Specialist Involvement Based on Organ System Affected

• A neurologist is required when peripheral or autonomic nervous system involvement is present 18
• Transplant specialists are needed for evaluation of stem cell transplantation in AL amyloidosis or organ transplantation in advanced cases 19
• Palliative care specialists are important for symptom management and quality of life optimization 20

Collaborative Care Model

• The American College of Cardiology emphasizes that effective management of amyloidosis requires close collaboration between specialists due to the multisystem nature of the disease 14, 18
• Hematologists and cardiologists collaborate for interpretation of abnormal monoclonal protein screens 14, 21
• Nephrologists contribute through managing nephrotic syndrome and chronic kidney disease, and interpreting serum free light chain concentrations in kidney impairment 16

Common Pitfalls in Specialist Care

• Delayed diagnosis can occur due to nonspecific symptoms, and early specialist referral is critical 21
• Fragmented care can lead to suboptimal treatment without coordination between specialists 18
• Overlooking cardiac involvement is a common pitfall, as heart involvement drives prognosis 14

Treatment Approach

• The American College of Cardiology recommends hematologist-directed treatment targeting the plasma cell clone for AL amyloidosis, with daratumumab-CyBorD as first-line therapy for most patients 19
• High-dose melphalan with stem cell transplantation is considered for eligible patients with AL amyloidosis 19
• Cardiologist-directed treatment is required for cardiac manifestations of ATTR amyloidosis 18

Evaluating and Managing Amyloidosis in Multiple Myeloma Patients

Recognition of the MM-Amyloidosis Overlap

• Approximately 10-15% of multiple myeloma patients also have AL amyloidosis, according to the American College of Cardiology 22
• Conversely, 10% of AL amyloidosis cases are associated with multiple myeloma, as stated by the American College of Cardiology 22
• The plasma cell burden in multiple myeloma is generally higher than in AL amyloidosis, but amyloid deposition remains an uncommon clinical feature in typical myeloma, as noted by the American College of Cardiology 22
• Patients with both conditions are more fragile than those with myeloma alone due to multiple severe organ dysfunctions, as reported by Haematologica 23, 24

Clinical Red Flags Requiring Amyloidosis Evaluation

• Any multiple myeloma patient presenting with restrictive cardiomyopathy or unexplained heart failure should undergo immediate evaluation for AL amyloidosis, as recommended by the American College of Cardiology 25, 26
• Unexplained proteinuria or nephrotic syndrome in multiple myeloma patients requires evaluation for AL amyloidosis, according to the American College of Cardiology 25, 26
• Macroglossia or submandibular gland enlargement in multiple myeloma patients is a red flag for AL amyloidosis, as stated by the American College of Cardiology 22, 25
• Periorbital purpura (periorbital ecchymoses) in multiple myeloma patients warrants evaluation for AL amyloidosis, as recommended by the American College of Cardiology 25, 26
• Peripheral neuropathy with autonomic features or bilateral carpal tunnel syndrome in multiple myeloma patients requires evaluation for AL amyloidosis, according to the American College of Cardiology 25, 26
• Acquired factor X deficiency with coagulopathy in multiple myeloma patients is a red flag for AL amyloidosis, as stated by the American College of Cardiology 22, 25

Diagnostic Approach

• Perform comprehensive monoclonal protein screening with all three tests simultaneously, including serum free light chain assay (sFLC) with kappa/lambda ratio, serum immunofixation electrophoresis (SIFE), and urine immunofixation electrophoresis (UIFE), as recommended by the American College of Cardiology and the National Comprehensive Cancer Network 25, 26, 27
• Mass spectrometry (LC-MS/MS) is the gold standard for identifying the amyloid precursor protein, with 88% sensitivity and 96% specificity, as stated by the American College of Cardiology 25, 26

Treatment Implications

• Treatment must target the plasma cell clone using anti-plasma cell therapies derived from multiple myeloma regimens, as recommended by the American College of Cardiology 22
• For patients aged <60 years with AL amyloidosis and ≤2 organs involved without severe cardiac involvement, high-dose chemotherapy followed by stem cell transplantation should be considered, as reported by Haematologica 23, 24
• For patients aged 60-65 years with serum creatinine ≥2 mg/dL, reduce melphalan dose to 100 mg/m² and proceed with extreme caution, as recommended by Haematologica 23, 24
• Melphalan 0.22 mg/kg plus high-dose dexamethasone 40 mg orally days 1-4 every 28 days achieves high response rates (67% hematologic response, 33% complete remission), as reported by the National Comprehensive Cancer Network and Haematologica 27, 24

Cardiac Monitoring During Treatment

• Close collaboration between hematology and cardiology is mandatory for monitoring cardiotoxicity of AL amyloidosis therapies, as recommended by the American College of Cardiology 22, 28, 29
• Assessment of cardiovascular fitness for high-dose melphalan with stem cell transplantation is crucial, as stated by the American College of Cardiology 28, 29

Organ-Specific Management Considerations

• Avoid NSAIDs and IV contrast to prevent further renal dysfunction in patients with renal involvement, as recommended by the National Comprehensive Cancer Network 27
• Refer to gastroenterology for significant malnutrition or unexplained weight loss, severe nausea, vomiting, diarrhea, constipation, or GI bleeding, as recommended by the American College of Cardiology 22, 29

Treatment of Cardiac Amyloidosis

Diagnosis and Typing

• Accurate typing of the amyloid protein is mandatory before initiating any disease-specific therapy, as AL and ATTR amyloidosis require completely different treatments, according to the American Heart Association 30
• Mass spectrometry (LC-MS/MS) of tissue biopsy is the gold standard for amyloid typing, with 88% sensitivity and 96% specificity, as recommended by the American College of Cardiology 31

Disease-Specific Treatment for AL Cardiac Amyloidosis

• Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) is the preferred first-line treatment for AL cardiac amyloidosis, achieving very good partial response or better in 78.5% of patients, according to the American College of Cardiology 31
• The goal is to eradicate the pathological plasma cell clone and remove amyloidogenic light chains from circulation, as stated by the American Society of Hematology 31

Disease-Specific Treatment for ATTR Cardiac Amyloidosis

• Tafamidis is indicated for treatment of ATTR cardiomyopathy in adults with NYHA Class I-III symptoms to reduce cardiovascular mortality and cardiovascular-related hospitalization, as approved by the FDA and recommended by the American College of Cardiology 31

Supportive Cardiac Management

• Judicious diuresis remains the cornerstone of heart failure therapy in cardiac amyloidosis, but standard heart failure medications must be used with extreme caution or avoided, according to the American Heart Association 30
• Anticoagulation is reasonable in patients with cardiac amyloidosis and atrial fibrillation to reduce stroke risk, independent of CHA₂DS₂-VASc score, as recommended by the American College of Cardiology 30

Treatment of Systemic Amyloidosis

Eligibility Criteria for Autologous Stem Cell Transplantation

• The International Myeloma Society recommends that eligibility criteria for autologous stem cell transplantation in AL amyloidosis include Mayo stage 1-2, age <65 years, performance status 0-2, eGFR >50 ml/min/1.74 m², NYHA class <3, ejection fraction >40-45%, systolic blood pressure >90 mmHg, DLCO >50%, and bone marrow plasma cells >10% 32, 33

Supportive Care Measures

• The American Society of Hematology recommends salt restriction, daily weight monitoring, diuretics, ACE inhibitors at lowest dose, elastic compression stockings, midodrine for refractory hypotension, amiodarone as antiarrhythmic, nutritional support, octreotide for diarrhea, and gabapentin or pregabalin for neuropathic pain in patients with AL amyloidosis 32

Risk of NSAIDs and IV Contrast

• The National Comprehensive Cancer Network recommends avoiding NSAIDs and IV contrast in patients with renal involvement to prevent further renal dysfunction 33